TOURMALINE BIO INC (TRML) Stock Price, Quote, News and Overview
NASDAQ:TRML - Nasdaq - US89157D1054 - Common Stock - Currency: USD
TRML Quote, Performance and Key Statistics
23.34
+0.65 (+2.86%)
The current stock price of TRML is 23.34 USD. In the past month the price increased by 47.44%. In the past year, price increased by 46.42%.
TRML Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.43 | 334.40B | ||
| AMGN | AMGEN INC | 14.52 | 162.05B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.75B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.48B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.52 | 59.88B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 44.31B | ||
| ARGX | ARGENX SE - ADR | 104.34 | 36.65B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.67 | 32.46B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.46B | ||
| INSM | INSMED INC | N/A | 19.95B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.80B | ||
| NTRA | NATERA INC | N/A | 19.25B |
Related stock screener links
About TRML
Company Profile
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2021-05-07. The firm is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. The company is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.
Company Info
TOURMALINE BIO INC
27 West 24th Street, Suite 702
New York City NEW YORK US
Employees: 70
Phone: 15023989250.0
TOURMALINE BIO INC / TRML FAQ
What is the stock price of TOURMALINE BIO INC today?
The current stock price of TRML is 23.34 USD. The price increased by 2.86% in the last trading session.
What is the ticker symbol for TOURMALINE BIO INC stock?
The exchange symbol of TOURMALINE BIO INC is TRML and it is listed on the Nasdaq exchange.
On which exchange is TRML stock listed?
TRML stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TOURMALINE BIO INC stock?
17 analysts have analysed TRML and the average price target is 56.81 USD. This implies a price increase of 143.42% is expected in the next year compared to the current price of 23.34. Check the TOURMALINE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TOURMALINE BIO INC worth?
TOURMALINE BIO INC (TRML) has a market capitalization of 599.60M USD. This makes TRML a Small Cap stock.
How many employees does TOURMALINE BIO INC have?
TOURMALINE BIO INC (TRML) currently has 70 employees.
What are the support and resistance levels for TOURMALINE BIO INC (TRML) stock?
TOURMALINE BIO INC (TRML) has a support level at 19.52. Check the full technical report for a detailed analysis of TRML support and resistance levels.
Should I buy TOURMALINE BIO INC (TRML) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TRML, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TRML, evaluating the profitability, health, valuation and growth aspects
- TOURMALINE BIO INC (TRML) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TOURMALINE BIO INC (TRML) Sales and EPS estimates to see what analysts future expectations are.
- TOURMALINE BIO INC (TRML) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TOURMALINE BIO INC (TRML) Insider and Institutional Ownership to learn about the owners and their transactions.
- TOURMALINE BIO INC (TRML) Stock Chart to make your own analysis
- TOURMALINE BIO INC (TRML) Latest news and press-releases to stay up to date.
Does TOURMALINE BIO INC (TRML) stock pay dividends?
TRML does not pay a dividend.
When does TOURMALINE BIO INC (TRML) report earnings?
TOURMALINE BIO INC (TRML) will report earnings on 2025-08-07, before the market open.
What is the Price/Earnings (PE) ratio of TOURMALINE BIO INC (TRML)?
TOURMALINE BIO INC (TRML) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.21).
What is the Short Interest ratio of TOURMALINE BIO INC (TRML) stock?
The outstanding short interest for TOURMALINE BIO INC (TRML) is 15.04% of its float. Check the ownership tab for more information on the TRML short interest.
TRML Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TRML. When comparing the yearly performance of all stocks, TRML is one of the better performing stocks in the market, outperforming 90.75% of all stocks.
TRML Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TRML. While TRML has a great health rating, there are worries on its profitability.
TRML Financial Highlights
Over the last trailing twelve months TRML reported a non-GAAP Earnings per Share(EPS) of -3.21. The EPS increased by 39.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.82% | ||
| ROE | -29.61% | ||
| Debt/Equity | 0 |
TRML Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to TRML. The Buy consensus is the average rating of analysts ratings from 17 analysts.